Institute of Experimental and Clinical Therapeutics, Department of Physiology, Health Science University Center, University of Guadalajara, Guadalajara, Jalisco, Mexico.
Multidisciplinary Health Research Center, Biomedical Sciences Department, University Center of Tonala, University of Guadalajara, Tonala, Jalisco, Mexico.
J Med Food. 2022 Jun;25(6):645-651. doi: 10.1089/jmf.2021.0164. Epub 2022 May 4.
The aim of this study was to evaluate the effect of (MC) administration on anthropometric measures in patients with obesity. A randomized, double-blind, placebo-controlled pilot clinical trial was carried out in 24 patients with obesity. Twelve patients randomly received MC (2000 mg/day) for 12 weeks, and 12 patients received placebo. Body weight (BW), body mass index (BMI), waist circumference (WC), body fat percentage, as well as clinical and laboratory determinations, were evaluated before and after the intervention. Results showed that while reductions in BW, BMI, WC, and body fat percentage were observed in the MC group, these differences did not reach statistical significance. Significant decreases in triglycerides (TG) (1.9 ± 0.6 mM vs. 1.7 ± 0.7 mM, ≤ .05) and very low-density lipoprotein (VLDL) (0.4 ± 0.1 mM vs. 0.3 ± 0.1 mM, ≤ .05) levels were found after the intervention with MC. In contrast, significant increases in BW (83.0 ± 10.7 kg vs. 84.6 ± 9.1 kg, ≤ .05) and BMI (31.9 ± 1.5 kg/m vs. 33.0 ± 1.3 kg/m, ≤ .05) were observed in the placebo group. In conclusion, no significant reductions in BW, BMI, WC, and body fat percentage were observed after MC administration; however, MC significantly decreased TG and VLDL levels. The protocol was registered at ClinicalTrials.gov with the identifier NCT04916379.
本研究旨在评估 （MC） 给药对肥胖患者人体测量学指标的影响。在 24 名肥胖患者中进行了一项随机、双盲、安慰剂对照的初步临床试验。12 名患者随机接受 MC（2000mg/天）治疗 12 周，12 名患者接受安慰剂。在干预前后评估体重（BW）、体重指数（BMI）、腰围（WC）、体脂百分比以及临床和实验室检测结果。结果显示，MC 组 BW、BMI、WC 和体脂百分比均有降低，但差异无统计学意义。MC 干预后，三酰甘油（TG）（1.9±0.6mM 对 1.7±0.7mM，≤.05）和极低密度脂蛋白（VLDL）（0.4±0.1mM 对 0.3±0.1mM，≤.05）水平显著降低。相比之下，安慰剂组 BW（83.0±10.7kg 对 84.6±9.1kg，≤.05）和 BMI（31.9±1.5kg/m 对 33.0±1.3kg/m，≤.05）显著增加。结论：MC 给药后 BW、BMI、WC 和体脂百分比无显著降低；但 MC 显著降低 TG 和 VLDL 水平。该方案在 ClinicalTrials.gov 上注册，标识符为 NCT04916379。
